CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Change in Directorate
Re-appointment of Mr. Ganesh Nayak as an Executive Director subject to approval of shareholders at the ensuing Annual General Meeting19-06-2020
19-06-2020
CADILA HEALTHCARE LTD. - 532321 - Outcome of Board Meeting (AGM on August 27, 2020)
Cadila Healthcare Ltd has informed BSE about Outcome of Board Meeting held on June 19, 2020.19-06-2020
CADILA HEALTHCARE LTD. - 532321 - Audited Financial Results For The Quarter/Year Ending March 31, 2020
Outcome of Board Meeting19-06-2020
No shortage of dexamethasone in India, Chinese raw materials remain key
Sources within Zydus Cadila told Moneycontrol that the company has enough capacity to meet domestic need17-06-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst Call on June 19, 202017-06-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement16-06-2020
Zydus Cadila gets USFDA approval to market generic version of Deferasirox tablets
The approval by the US Food and Drug Administration (USFDA) for Deferasirox tablets is for multiple strengths of 90 mg, 180 mg and 360 mg, Cadila Healthcare said in a regulatory filing.16-06-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Deferasirox Tablets16-06-2020
CADILA HEALTHCARE LTD. - 532321 - Board Meeting Intimation for Audited Financial Results For The Quarter / Year Ended On March 31, 2020.
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/06/2020 ,inter alia, to consider and approve Audited Financial results for the quarter / year ended on March 31, 2020.15-06-2020